http://flip.it/1yr5Gs: flip.it/1yr5Gs - Advanced Prostate...
http://flip.it/1yr5Gs
Olaparib could help for a while when the cancers have mutations , mainly BRCA & PALB2 and others like ATM, CDK12 etc, .
""Olaparib is active for patients with mCRPC who have a pathogenic alteration in DNA repair genes, specifically for patients with mutations in BRCA1/2, PALB2, ATM, and CDK12. Patients with BRCA1/2 variants appear to have the greatest benefit. It will be interesting to see how combination studies compare with single-agent PARP inhibition – early studies have shown that olaparib in combination with abiraterone may be beneficial regardless of mutational profile and checkpoint inhibitors may also represent a rational partner as well, with preclinical evidence showing that PARP inhibition may lead to adaptive upregulation of PD-L1 expression.2,3 Given the compelling body of work supporting the use of olaparib in certain genomic subsets of patients, it is only a matter of time before PARP inhibitors become one of the first biomarker-guided therapy for patients with mCRPC.""
This is about Olaparib being effective with men with the BRACA 1/2 and ATM gene defects. Royal Marsden Hospital research report on a 4500 men trial.
